Milestone Pharmaceuticals Inc. (MIST) Current Ratio
- Current ratio · latest quarter: Value 8.13×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.13× | Current assets / current liabilities. $180.33M ÷ $22.18M ≈ 8.13× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 180.33M USD | Assets, Current |
| Current obligations | 22.18M USD | Liabilities, Current |
| Cash and equivalents | 169.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 2.72M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 4.72M USD | Inventory, Net |
| Payables | 8.45M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $180.33M | $22.18M | $169.73M | (m) | $2.72M | $4.72M | $8.45M | (m) | 8.13× |
| 2026-03-31 | $192.25M | $20.94M | $71.32M | (m) | $1.60M | $1.83M | $10.02M | (m) | 9.18× |
| 2025-12-31 | $111.92M | $13.98M | $73.05M | (m) | (m) | $648.00K | $5.64M | (m) | 8.01× |
| 2025-09-30 | $86.67M | $10.52M | $46.69M | (m) | (m) | (m) | (m) | (m) | 8.24× |
| 2025-06-30 | $46.17M | $9.28M | $42.50M | (m) | (m) | (m) | (m) | (m) | 4.97× |
| 2025-03-31 | $60.48M | $12.96M | $45.09M | (m) | (m) | (m) | (m) | (m) | 4.67× |
| 2024-12-31 | $73.93M | $8.13M | $25.31M | (m) | (m) | (m) | (m) | (m) | 9.10× |
| 2024-09-30 | $80.99M | $5.26M | $12.80M | (m) | (m) | (m) | (m) | (m) | 15.40× |
| 2024-06-30 | $87.36M | $4.57M | $13.26M | (m) | (m) | (m) | (m) | (m) | 19.13× |
| 2024-03-31 | $93.97M | $4.13M | $10.13M | (m) | (m) | (m) | (m) | (m) | 22.75× |
| 2023-12-31 | $73.03M | $7.23M | $13.76M | (m) | (m) | (m) | (m) | (m) | 10.11× |
| 2023-09-30 | $84.80M | $8.11M | $9.88M | (m) | (m) | (m) | (m) | (m) | 10.45× |
| 2023-06-30 | $94.57M | $6.81M | $32.59M | (m) | (m) | (m) | (m) | (m) | 13.89× |
| 2023-03-31 | $108.51M | $7.96M | $73.95M | (m) | (m) | (m) | (m) | (m) | 13.63× |
| 2022-12-31 | $71.80M | $6.14M | $7.64M | (m) | (m) | (m) | (m) | (m) | 11.70× |
| 2022-09-30 | $82.92M | $6.52M | $37.29M | (m) | (m) | (m) | (m) | (m) | 12.71× |
| 2022-06-30 | $90.50M | $4.26M | $63.24M | (m) | (m) | (m) | (m) | (m) | 21.26× |
| 2022-03-31 | $104.97M | $4.61M | $92.24M | (m) | (m) | (m) | (m) | (m) | 22.77× |
| 2021-12-31 | $118.92M | $6.78M | $114.14M | (m) | (m) | (m) | (m) | (m) | 17.55× |
| 2021-09-30 | $132.76M | $5.85M | $111.43M | (m) | (m) | (m) | (m) | (m) | 22.71× |
| 2021-06-30 | $144.39M | $5.33M | $97.79M | (m) | (m) | (m) | (m) | (m) | 27.10× |
| 2021-03-31 | $137.24M | $5.82M | $71.86M | (m) | (m) | (m) | (m) | (m) | 23.60× |
| 2020-12-31 | $148.69M | $6.16M | $72.31M | (m) | (m) | (m) | (m) | (m) | 24.14× |
| 2020-09-30 | $107.42M | $5.88M | $46.91M | (m) | (m) | (m) | (m) | (m) | 18.27× |
| 2020-06-30 | $92.41M | $4.99M | $53.43M | (m) | (m) | (m) | (m) | (m) | 18.51× |
| 2020-03-31 | $104.32M | $5.37M | $101.82M | (m) | (m) | (m) | (m) | (m) | 19.44× |
| 2019-12-31 | $122.50M | $8.33M | $119.82M | (m) | (m) | (m) | (m) | (m) | 14.71× |
| 2019-09-30 | $140.97M | $8.84M | $106.50M | (m) | (m) | (m) | (m) | (m) | 15.95× |
| 2019-06-30 | $151.55M | $6.46M | $110.82M | (m) | (m) | (m) | (m) | (m) | 23.45× |
| 2019-03-31 | $77.28M | $4.15M | $71.24M | (m) | (m) | (m) | (m) | (m) | 18.61× |
| 2018-12-31 | $88.05M | $4.53M | $85.95M | (m) | (m) | (m) | (m) | (m) | 19.42× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |